TrialDiabetes, obesity & metabolism2022

Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.

Sean Wharton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.